Vertex Pharmaceuticals Stock Surges to 168th Most Actively Traded Amid FDA Approval and Gene Editing Expansion

On June 10, 2025, Vertex Pharmaceuticals Incorporated (VRTX) saw a significant surge in trading volume, with a total of $580 million in shares exchanged, marking a 42.03% increase from the previous day. This placed Vertex among the top 168 most actively traded stocks for the day. The company's stock price also rose by 1.20%.

Vertex Pharmaceuticals Incorporated has recently announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its new drug, VX-123, which is designed to treat a rare genetic disorder. This approval is a significant milestone for the company, as it expands its portfolio of treatments for rare diseases. The drug is expected to be available to patients by the end of the year.

In addition to the FDA approval, Vertex has also announced that it will be expanding its research and development efforts in the field of gene editing. The company has partnered with a leading academic institution to develop new technologies that could revolutionize the treatment of genetic disorders. This partnership is expected to accelerate the development of new therapies and bring hope to patients suffering from rare diseases.

Vertex's recent developments have been well-received by investors, who see the company's commitment to innovation and its expanding portfolio of treatments as a strong indicator of future growth. The company's stock price has been on an upward trajectory in recent months, and analysts expect this trend to continue as Vertex continues to make strides in the field of genetic therapies.